Abstract
In order to investigate the predictive value of in vitro MTT assay for directing chemotherapy of breast cancer patients, from 1992 to 1995, 156 advanced breast cancer patients who had evaluable lesions were recruited for a prospective study. Of them 83 had MTT assay before chemotherapthe 73 patients in the MTT sensitive group received chemotherapy according to the result of the MTT assay. The other 10 patients in the MTT resistant group and 73 patients in the control group were given chemotherapy according to clinicians' discretion. The response rate in the MTT sensitive group was 76.7% (56/73). There was statistically significant difference as compared with 0 (0/10) in the MTT resistant group and 43.8% (32/73) in the control group. Between in vitro and in vivo, the overall coincident rate was 79.5%[(56+10)/83]. In the MTT sensitive group, the response rate of the subgroups of lesions and the chemotherapy regiments tended to be higher than that in the control group. Patients in the MTT sensitive group had longer response and survival than those in the control group. However, there was no statistical difference in the median response duration and the median survival between the two groups. Further exploration of in vitro chemosensitivity testing by MTT assay for patients with advanced breast cancer is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bellamy WT: Prediction of response to drug therapy of cancer: a review of in vitro assays. Drugs 44: 690–708, 1992
Sargent J, Elgie A, Taylor CG, Wilson J, Alton P, Hill JG: The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay. Contrib Gynecol Obstet 19: 64–75, 1994
Wilson JK, Sargent JM, Elgie AW, Hill JG, Taylor CG:A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 62: 189–194, 1990
Yamaue H, Tanimura H, Nakamori M, Noguchi K, Iwahashi M, Tani M, Hotta T, Murakami K, Ishimoto K: Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. Dis Colon Rectum 39: 416–422, 1996
Suto A, Kubota T, Shimoyama Y, Ishibiki K, Abe O: MTT assay with reference to the clinical effect of chemotherapy. J Surg Oncol 42: 28–32, 1989
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63, 1983
Hwang WS, Chen LM, Huang SH, Wang CC, Tseng MT: Prediction of chemotherapy response in human leukemia using in vitro chemosensitivity test. Leuk Res 17: 685–688, 1993
Tonn JC, Schachenmayr W, Kraemer HP: In vitro chemosensitivity test of malignant gliomas: Clinical relevance of test results independent of adjuvant chemotherapy. Anticancer Res 14: 1371–1375, 1994
Campling BG, Pym J, Baker HM, Cole SPC, Lam YM: Chemosensitivity testing of small cell lung cancer using the MTT assay. Br J Cancer 63: 75–83, 1991
Miller AB, Hoogstraten MB, Staquet M, Winkler A: Reporting result of cancer treatment. Cancer 47: 207–211, 1981
Xu JM, Song ST, Tang ZM, Liu XQ, Jiang ZF, Zhou L, Li YB, Huang Y: Evaluation of chemosensitivities of antitumor drugs using the MTT assay in fresh human breast cancers. Breast Cancer Res Treat: 49: 251–259 1998
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 475–481, 1958
Pronzato P, Queirolo P, Landucci M, Vaira F, Vigani A, Gipponi M, Cafiero F: Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Breast Cancer Res Treat 42: 183–186, 1997
Iambelli M, Demicheli R, Candis DD, Antonelli G, Giacobone A, Terenziani M, Laffranchi A, Garbagnati F, Biasi S, Bonadonna G: Five day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 44: 255–260, 1997
Slater TF, Sawyer B, Strauli UD: Studies on succinatetetrazolium reductase systems III. Points of coupling of four different tetrazolium salts. Biochim Biophys Acta 77: 383–388, 1963
Kusumoto T, Sakaguchi Y, Machara Y, Nakashima T, Furusawa M, Sugimachi K: Comparison of in vitro anticancer chemosensitivity between human squamous cell carcinoma and adenocarcinoma. Oncology 49: 343–346, 1992
Hoffman RM: in vitro sensitivity assays in cancer: a review, analysis, and prognosis. J Clin Lab Analy 5: 133–143, 1991
Dowsett M: Endocrine treatment of advanced breast cancer. Acta Oncol 35 (Suppl 6): 68–72, 1996
Robert NJ, Beveridge RA: Management of recurrent breast cancer. Obstet Gynecol Clin North Am 21: 709–719, 1994
Venturini M, Mastro LD, Melioli G, Balleari E, Garrone O, Pasquetti W, Bason C, Ghio R, Bruzzi P: Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicine, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy. Cancer 74: 2300–2306, 1994
Dillman RO, Barth NM, Nayak SK, Deleon C, O'Connor A, Morrelli L: High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treat 37: 277–289, 1996
Crown J, Kritz A, Vahdat L, Reich L, Moore M, Hamilton N, Schneider L, Harrison M, Gilewski T, Hudis C, Gulatis, Norton L: Rapid administeration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 11: 1144–1149, 1993
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xu, J., Song, S., Tang, Z. et al. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res Treat 53, 77–85 (1999). https://doi.org/10.1023/A:1006122912146
Issue Date:
DOI: https://doi.org/10.1023/A:1006122912146